KLP Kapitalforvaltning AS Has $16.01 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• KLP Kapitalforvaltning AS increased its stake in Alnylam Pharmaceuticals by 12.4% during Q2, now holding 49,100 shares valued at $16.01 million.
• An increase in price targets for Alnylam Pharmaceuticals was noted, with estimates now reaching as high as $515.05 from various Wall Street analysts.
• Insiders sold a significant amount of stock recently, with 98,144 shares traded for a total of $44.16 million in the last ninety days.

KLP Kapitalforvaltning AS lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 12.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 49,100 shares of the biopharmaceutical company's stock after acquiring an additional 5,400 shares during the quarter. KLP Kapitalforvaltning AS's holdings in Alnylam Pharmaceuticals were worth $16,011,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Bayforest Capital Ltd grew its holdings in Alnylam Pharmaceuticals by 14.6% in the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 39 shares in the last quarter. Fulton Bank N.A. grew its stake in shares of Alnylam Pharmaceuticals by 3.3% in the second quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company's stock valued at $463,000 after acquiring an additional 46 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of Alnylam Pharmaceuticals by 10.3% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company's stock worth $142,000 after purchasing an additional 49 shares in the last quarter. Edmond DE Rothschild Holding S.A. grew its position in shares of Alnylam Pharmaceuticals by 18.2% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 49 shares in the last quarter. Finally, Lindbrook Capital LLC grew its position in shares of Alnylam Pharmaceuticals by 9.2% during the 1st quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock worth $161,000 after purchasing an additional 50 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Morgan Stanley increased their price objective on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an "equal weight" rating in a research note on Monday. JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Royal Bank Of Canada increased their price target on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an "outperform" rating in a research report on Friday, September 19th. Finally, Evercore ISI increased their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an "outperform" rating in a research report on Thursday, September 11th. Twenty-four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $448.04.

Insider Activity

In other news, EVP Tolga Tanguler sold 1,405 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $635,130.25. Following the sale, the executive vice president directly owned 27,438 shares of the company's stock, valued at approximately $12,403,347.90. This trade represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the sale, the executive vice president owned 25,231 shares in the company, valued at approximately $11,405,673.55. This represents a 8.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,144 shares of company stock valued at $44,160,261. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $450.68 on Thursday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $484.21. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a market capitalization of $59.08 billion, a P/E ratio of -182.46 and a beta of 0.36. The company's 50 day moving average price is $448.91 and its two-hundred day moving average price is $342.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same quarter last year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.